Cara Therapeutics, Inc. (CARA)
| Market Cap | 1.42B |
| Revenue (ttm) | 135.08M |
| Net Income (ttm) | 8.41M |
| Shares Out | 47.41M |
| EPS (ttm) | 0.18 |
| PE Ratio | 161.07 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $28.51 |
| Previous Close | $28.31 |
| Change ($) | 0.20 |
| Change (%) | 0.71% |
| Day's Open | 28.00 |
| Day's Range | 27.82 - 28.73 |
| Day's Volume | 632,804 |
| 52-Week Range | 12.30 - 29.65 |
STAMFORD, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevi...
Cara (CARA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
The biotech stock is being added to an important small-cap index.
The shares of Cara Therapeutics Inc (NASDAQ:CARA) are up 13.1% to trade at $23.82 at last check -- their highest level in over a year -- on reports that the equity will be added to the S&P 600 SmallCap...
Investors getting ready for another busy day of trading need to make sure they know the biggest pre-market stock movers before markets open. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gain...
STAMFORD, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevi...
ST. GALLEN, Switzerland and STAMFORD, Conn., March 30, 2021 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the Eur...
The FDA accepts Cara Therapeutics (CARA) and Vifor Pharma's NDA for Korsuva injection under a priority review to treat moderate-to-severe pruritus in hemodialysis patients. Shares rise.
STAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has acce...
– U.S. FDA Accepts NDA Filing for KORSUVA™ Injection in CKD-aP –
On Thursday, February 25, Cara Therapeutics (NASDAQ:CARA) will release its latest earnings report. Decipher the announcement with Benzinga's help.
STAMFORD, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
STAMFORD, Conn., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...
These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021. The post 6 Cannabis Stocks to Buy as the U.S. Softens Its Sta...
STAMFORD, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...
The opioid industry is an ~$50 billion annual business, but opioids are very harmful to the body and extremely addictive. CARA has a drug that is finishing its trials and expectation is that an NDA will...
- Topline data expected in first half of 2021 -
STAMFORD, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2020 Results - Earnings Call Transcript
Cara (CARA) delivered earnings and revenue surprises of 48.53% and 86.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
– Conference call today at 4:30 p.m. ET –
STAMFORD, Conn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...
Cara (CARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Results from global KALM-2 p ivotal Phase 3 t rial of KORSUVA ™ Injection in h emodialysis p atients with p ruritus to be presented –
ST GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
- Cara to Host Conference Call Today at 8:30 am EDT -
STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2020 Results - Earnings Call Transcript
Cara (CARA) delivered earnings and revenue surprises of 20.59% and 2.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
– Conference call today at 4:30 p.m. ET –
STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allev...
STAMFORD, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevi...
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These marijuana stocks on the Nasdaq are top for value, growth, and performance for July 2020.
STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allev...
Both of these biotechs could have big catalysts on the way.
These companies are all surprising a few doubters lately.
- Patient enrollment increased approximately 28% to maintain > 80% statistical power for primary endpoint and key registration endpoint of > 4-point improvement responder analysis -
These are the NASDAQ-listed marijuana stocks with the best value, fastest growth, and most momentum for June.
Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2020 Results - Earnings Call Transcript
Cara (CARA) delivered earnings and revenue surprises of 1.59% and 67.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Which stock wins in a battle between these two clinical-stage biotechs?
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company plans to submit its pruritis drug for FDA and EMA approval later this year.
As of late, it has definitely been a great time to be an investor in Cara Therapeutics.
About CARA
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-assoc... [Read more...]
| Industry Biotechnology | IPO Date Jan 31, 2014 |
| CEO Derek Chalmers | Employees 80 |
| Stock Exchange NASDAQ | Ticker Symbol CARA |
Analyst Forecasts
According to 8 analysts, the average rating for CARA stock is "Buy." The 12-month stock price forecast is 35.13, which is an increase of 23.22% from the latest price.